



Patient ID SA00076110	Patient Name SAMPLEREPORT, FNSUR A	Birth Date 1981-08-04	Gender M	Age 34
Order Number SA00076110	Client Order Number SA00076110	Ordering Physician client, client	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 06 Jun 2016 13:00		

NASH FibroSure

Fibrosis Score

 0.31
High

Y060
Reference Value
0.00–0.21

Fibrosis Stage

F3-Bridging fibrosis with many septa

Y060

Steatosis Score

 1.66
High

Y060
Reference Value
0.00–0.30

Steatosis Grade

S3 - Marked or Severe Steatosis

Y060

NASH Score

15.32

Y060
Reference Value
0.25

NASH Grade

N2 - NASH

Y060

Height (in inches):

74 Inches


Y060

Weight (in pounds):

185 LBS


Y060

Alpha 2-Macroglobulins, Qn

 90 mg/dL
Low


Y060
Reference Value
110–276

Haptoglobin

 502 mg/dL
High

Y060
Reference Value
34–200

Apolipoprotein A-1

 220 mg/dL
High

Y060
Reference Value
101–178

Bilirubin, Total

 19.2 mg/dL
Crit

Y060
Reference Value
0.0–1.2

GGT

22 IU/L

Y060
Reference Value
0–65

ALT (SGPT) P5P

12 IU/L


Y060
Reference Value
0–55

AST (SGOT) P5P

19 IU/L


Y060
Reference Value
0–40

Cholesterol, Total

 85 mg/dL
Low

Y060
Reference Value
100–199

Glucose, Serum

 601 mg/dL
Crit

Y060
Reference Value
65–99

Triglycerides

102 mg/dL

Y060
Reference Value
0–149

Performing Site Legend

Code	Laboratory	Address
Y060	LabCorp Burlington	1447 York Court, Burlington, NC 27215

Patient ID SA00076110	Patient Name SAMPLEREPORT, FNSUR A	Birth Date 1981-08-04	Gender M	Age 34
Order Number SA00076110	Client Order Number SA00076110	Ordering Physician client, client	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 06 Jun 2016 13:00		

Interpretations:
Y060

Quantitative results of 10 biochemicals in combination with age, gender, height, and weight, are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0–1.0) of liver fibrosis (Metavir F0–F4), hepatic steatosis (0.0–1.0, S0–S3), and Non-Alcoholic Steato-Hepatitis (NASH) (0.0–0.75, N0–N2). The absence of steatosis (S<0.38) precludes the diagnosis of NASH.

Fibrosis marker: In a study of 171 Non-Alcoholic Fatty Liver Disease (NAFLD) patients where 23% had significant NAFLD fibrosis (Metavir F2–F4) and 11% had cirrhosis by liver biopsy, a fibrosis result of >0.3 yielded a sensitivity of 83% and a specificity of 78% for the detection of significant fibrosis(1).

Steatosis Marker: In a population of 744 patients (583 HCV, 18 HBV, 69 NAFLD, and 74 alcoholic disease patients), where 36% had significant steatosis (>5%) on a liver biopsy, a steatosis score >0.5 had a sensitivity of 71% and a specificity of 72% for identification of significant steatosis(2).

NASH marker: In a population of 257 NAFLD patients, where 62% had at least some NASH by liver biopsy, a prediction of NASH had a sensitivity of 88% for identifying NASH and a specificity of 50%(3).

Fibrosis Scoring:
Y060

<0.21 = Stage F0 - No fibrosis
 0.21–0.27 = Stage F0 - F1
 0.27–0.31 = Stage F1 - Portal fibrosis
 0.31–0.48 = Stage F1 - F2
 0.48–0.58 = Stage F2 - Bridging fibrosis with few septa
 0.58–0.72 = Stage F3 - Bridging fibrosis with many septa
 0.72–0.74 = Stage F3 - F4
 >0.74 = Stage F4 - Cirrhosis

Steatosis Grading
Y060

< 0.30 = S0 - No Steatosis
 0.30 to 0.38 = S0 - S1
 0.38 to 0.48 = S1 - Minimal Steatosis
 0.48 to 0.57 = S1 - S2
 0.57 to 0.67 = S2 - Moderate Steatosis
 0.67 to 0.69 = S2 - S3
 > 0.69 = S3 - Marked or Severe Steatosis

NASH Scoring
Y060

0.25 = N0 - Not NASH
 0.50 = N1 - Borderline or probable NASH
 0.75 = N2 - NASH

Limitations:
Y060

NASH FibroSure is recommended for patients with suspected non-alcoholic fatty liver disease. It is not recommended for patients with other liver diseases. It is also not recommended in patients with Gilbert Disease, acute hemolysis, acute viral hepatitis, drug induced hepatitis, genetic liver disease, autoimmune hepatitis and/or extra-hepatic cholestasis. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis.

Comment:
Y060

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

For questions regarding this report please contact customer service at 1–800–788–9223.

References:

1. Ratziu V. et al. Diagnostic Value of Biochemical Markers (FibroTest) for the prediction of Liver Fibrosis in patients with Non-Alcoholic Fatty Liver Disease. BMC Gastroenterology 2006; 6:6.
2. Poynard, T. et al. The Diagnostic Value of Biomarkers

Performing Site Legend

Code	Laboratory	Address
Y060	LabCorp Burlington	1447 York Court, Burlington, NC 27215



Patient ID SA00076110	Patient Name SAMPLEREPORT, FNSUR A	Birth Date 1981-08-04	Gender M	Age 34
Order Number SA00076110	Client Order Number SA00076110	Ordering Physician client, client	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 06 Jun 2016 13:00		

(Steato Test) for the Prediction of Liver Steatosis.
Comparative Hepatol. 2005; 4:10.
3. Poynard, T, Ratziu, Charlotte F, et al. Diagnostic value
of biochemical markers (NASH TEST) for the prediction of
non alcohol steato hepatitis in patients with non-

alcoholic fatty liver disease. BMC Gastroenterology 2006;
6:34 doi:10.1186/1471-230X-6-34.

Received: 07 Jun 2016 13:09

Reported: 09 Jun 2016 07:57

Performing Site Legend

Code	Laboratory	Address
Y060	LabCorp Burlington	1447 York Court, Burlington, NC 27215